RecruitingNot ApplicableNCT07539194

Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic Degenerative Meniscus Tears


Sponsor

Innate srl

Enrollment

25 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Evaluation of the performance and safety of a single-dose hyaluronic acid (Promovia hydro balance) in the treatment of non-traumatic degenerative meniscus tears


Eligibility

Min Age: 35 YearsMax Age: 75 Years

Inclusion Criteria7

  • \- Age between 35 and 75 years at the time of administration.
  • Presence of a symptomatic degenerative meniscus tear, not related to acute trauma, documented by MRI.
  • Positive meniscal tests.
  • Pain intensity NRS ≥ 4.
  • Willingness to participate in physical therapy or light exercise.
  • Informed consent received, understood, and signed by the patient for active participation in the study and for the processing of personal data.
  • Ability of the patient to understand the study conditions and to participate for the entire duration of the study.

Exclusion Criteria11

  • \- Patients with traumatic meniscus tears.
  • Patients with a meniscal tear requiring surgical treatment (FLAP tear, radial tear, RAMP tear).
  • Patients with severe knee osteoarthritis.
  • Patients with axial deviation greater than 10°.
  • Patients who have undergone meniscal or ligament surgery in the previous 12 months.
  • Patients with rheumatic diseases or chondrocalcinosis.
  • Patients with signs of possible infection in the affected joint or a skin disease involving the knee (e.g., dermatitis, psoriasis).
  • Patients with diabetes.
  • Patients with coagulopathies, platelet aggregation disorders, or those receiving oral anticoagulants or antiplatelet drugs.
  • Patients receiving intra-articular corticosteroids or hyaluronic acid in the previous 12 months.
  • Pregnant or breastfeeding patients.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPromovia Hydro Balance 100 mg, Hyaluronic acid sodium salt and trehalose

Promovia Hydro Balance 100 mg


Locations(1)

ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO

Milan, MI, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07539194